Device Trial Radar · NCT06733922
ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
224
Planned (sponsor's estimate)
Start
Nov 27, 2024
Primary completion
Mar 31, 2029
Study completion Mar 31, 2029
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNot on our public-company list
- Sponsor type
- Industry
- First posted
- Dec 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The exploratory ELIOS study aims to assess the value of novel investigational Eye Movement Biomarkers (EMBs) in tracking disease-related changes among a real-world cohort of Canadian patients with active RRMS, within the context of disease-modifying treatment (i.e., ofatumumab). To that end, the study will use the patented investigational, Eye Tracking Neurological Assessment (ETNA-ProgMS) SaMD (v1.0.11 or later), which has not yet received Health Canada approval, to reliably and accurately track eye movements with precision.
Conditions
- Relapsing Remitting Multiple Sclerosis (RRMS)
Interventions
ETNATM-ProgMSDevice
To that end, the study will use the patented investigational ETNATM-ProgMS SaMD (v1.0.11 or later), which has not yet received Health Canada approval, to reliably and accurately track eye movements with precision. Of note, investigational versions of this SaMD are used for the purpose of clinical research only and will not be commercialized.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 1- Change Eye Movement Biomarkers (EMB)Time frame: 6 months from baseline
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Calgary, Alberta, Canada · Recruiting
15 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.